Factors associated with buprenorphine versus methadone use in pregnancy

References

• Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000–2009. JAMA. 2012;307:1934–1940.
   PubMed Web of Science ®Google Scholar
• Almario CV, Seligman NS, Dysart KC, Berghella V, Baxter JK. Risk factors for preterm birth among opiate-addicted gravid women in a methadone treatment program. Am J Obstet Gynecol. 2009;201:326.e321–326.e326.
   Google Scholar
• Cleary BJ, Donnelly JM, Strawbridge JD, et al. Methadone and perinatal outcomes: a retrospective cohort study. Am J Obstet Gynecol. 2011;204:139.e131–139.e139.
   Google Scholar
• Finnegan LP, Connaughton JF Jr, Kron RE, Emich JP. Neonatal abstinence syndrome: assessment and management. Addictive diseases. 1975;2:141–158.
   PubMedGoogle Scholar
• Logan BA, Brown MS, Hayes MJ. Neonatal abstinence syndrome: treatment and pediatric outcomes. Clin Obstet Gynecol. 2013;56:186–192.
   PubMed Web of Science ®Google Scholar
• Dryden C, Young D, Hepburn M, Mactier H. Maternal methadone use in pregnancy: factors associated with the development of neonatal abstinence syndrome and implications for healthcare resources. BJOG. 2009;116:665–671.
   PubMed Web of Science ®Google Scholar
• Madden JD, Chappel JN, Zuspan F, Gumpel J, Mejia A, Davis R. Observation and treatment of neonatal narcotic withdrawal. Am J Obstet Gynecol. 1977;127:199–201.
   PubMed Web of Science ®Google Scholar
• Burns L, Conroy E, Mattick RP. Infant mortality among women on a methadone program during pregnancy. Drug Alcohol Rev. 2010;29:551–556.
   PubMed Web of Science ®Google Scholar
• Bandstra ES, Morrow CE, Mansoor E, Accornero VH. Prenatal drug exposure: infant and toddler outcomes. J Addict Dis. 2010;29:245–258.
   PubMed Web of Science ®Google Scholar
• Creanga AA, Sabel JC, Ko JY, et al. Maternal drug use and its effect on neonates: a population-based study in Washington State. Obstet Gynecol. 2012;119:924–933.
   PubMed Web of Science ®Google Scholar
• Dashe JS, Jackson GL, Olscher DA, Zane EH, Wendel GD Jr. Opioid detoxification in pregnancy. Obstet Gynecol. 1998;92:854–858.
   PubMed Web of Science ®Google Scholar
• Stewart RD, Nelson DB, Adhikari EH, et al. The obstetrical and neonatal impact of maternal opioid detoxification in pregnancy. Am J Obstet Gynecol. 2013;209:267 e261–265.
   Google Scholar
• Jones H, Finnegan L, Kaltenbach K. Methadone and buprenorphine for the management of opioid dependence in pregnancy. Drugs. 2012;72:747–757.
   PubMed Web of Science ®Google Scholar
• Jones HE, Deppen K, Hudak ML, et al. Clinical care for opioid-using pregnant and postpartum women: the role of obstetric providers. Am J Obstet Gynecol. 2014; 210:302–10.
   Web of Science ®Google Scholar
• National Institutes of Health, US Department of Health and Human Services. Effective Medical Treatment of Opiate Addiction. Effective Medical Treatment of Opiate Addiction. NIH Consens Statement 1997 Nov 17–19; 15(6):1–38.
   Google Scholar
• Metz V, Jagsch R, Ebner N, et al. Impact of treatment approach on maternal and neonatal outcome in pregnant opioid-maintained women. Hum Psychopharmacol Clin Exp. 2011;26:412–421.
   PubMed Web of Science ®Google Scholar
• Kakko J, Heilig M, Sarman I. Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend. 2008;96:69–78.
   PubMed Web of Science ®Google Scholar
• Fischer G, Ortner R, Rohrmeister K, et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction. 2006;101:275–281.
   PubMed Web of Science ®Google Scholar
• Lacroix I, Berrebi A, Garipuy D, et al. Buprenorphine versus methadone in pregnant opioid-dependent women: a prospective multicenter study. Eur J Clin Pharmacol. 2011;67:1053–1059.
   PubMed Web of Science ®Google Scholar
• Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363:2320–2331.
   PubMed Web of Science ®Google Scholar
• Moore BA, Fiellin DA, Barry DT, et al. Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients. J Gen Intern Med. 2007;22:527–530.
   PubMed Web of Science ®Google Scholar
• Fiellin DA, Schottenfeld RS, Cutter CJ, Moore BA, Barry DT, O'Connor PG. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. JAMA Intern Med. 2014;174:1947–1954.
   PubMed Web of Science ®Google Scholar
• Jones ES, Moore BA, Sindelar JL, O'Connor PG, Schottenfeld RS, Fiellin DA. Cost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patients. Drug Alcohol Depend. 2009;99:132–140.
   PubMed Web of Science ®Google Scholar
• Fiellin DA, Kleber H, Trumble-Hejduk JG, McLellan AT, Kosten TR. Consensus statement on office-based treatment of opioid dependence using buprenorphine. J Subst Abuse Treat. 2004;27:153–159.
   PubMed Web of Science ®Google Scholar
• Barry DT, Irwin KS, Jones ES, et al. Integrating buprenorphine treatment into office-based practice: a qualitative study. J Gen Intern Med. 2009;24:218–225.
   PubMed Web of Science ®Google Scholar
• Teruya C, Schwartz RP, Mitchell SG, et al. Patient perspectives on buprenorphine/naloxone: a qualitative study of retention during the Starting Treatment With Agonist Replacement Therapies (START) study. J Psychoactive Drugs. 2014;46:412–426.
   PubMed Web of Science ®Google Scholar
• Potter JS, Marino EN, Hillhouse MP, et al. Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from Starting Treatment With Agonist Replacement Therapies (START). J Stud Alcohol Drugs. 2013;74:605–613.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2008;(2):CD002207.
   PubMed Web of Science ®Google Scholar
• Fischer G, Gombas W, Eder H, et al. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction. 1999;94:1337–1347.
   PubMed Web of Science ®Google Scholar
• Harrell FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer; 2001.
   Google Scholar
• Box GEP, Draper NR. Empirical Model-Building and Response Surfaces. New York: John Wiley & Sons; 1987.
   Google Scholar
• Steyerberg EW. Clinical Prediction Models. New York: Springer; 2009.
   Google Scholar
• Hansen H, Siegel C, Case B, Bertollo D, DiRocco D, Galanter M. Variation in use of buprenorphine and methadone treatment by racial, ethnic, and income characteristics of residential social areas in New York City. J Behav Health Serv Res. 2013;40:367–377.
   PubMed Web of Science ®Google Scholar
• Jones ES, Fiellin DA. Women and opioid dependence treatment: office-based versus opioid treatment program-based care? Subst Abus. 2007;28:3–8.
   PubMedGoogle Scholar
• Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;(2):CD002207.
   PubMed Web of Science ®Google Scholar
• Whitley SD, Sohler NL, Kunins HV, et al. Factors associated with complicated buprenorphine inductions. J Subst Abuse Treat. 2010;39:51–57.
   PubMed Web of Science ®Google Scholar
• Jones HE, Heil SH, Baewert A, et al. Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. Addiction. 2012;107(Suppl 1):5–27.
   PubMed Web of Science ®Google Scholar
• Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA Psychiatry. 2014;71:821–826.
   PubMed Web of Science ®Google Scholar
• Terplan M, Smith EJ, Glavin SH. Trends in injection drug use among pregnant women admitted into drug treatment: 1994–2006. J Womens Health. 2010;19:499–505.
   Web of Science ®Google Scholar